Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancer
New Podcast
Skip to content
FOR INVESTORS
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Onvansertib
Pipeline
Clinical Programs
mCRC
mCRPC
mPDAC
Leadership
Management Team
Board of Directors
Scientific Advisory Board
Contact Us
For Investors
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Investor Relations
Press Releases
Events
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Get News Alerts by Email
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Jun 5, 2023
Cardiff Oncology to Present at the Jefferies Healthcare Conference
May 4, 2023
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
Mar 28, 2023
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer
Mar 6, 2023
Cardiff Oncology Formally Introduces Scientific Advisory Board
Mar 2, 2023
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
79
»